for prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction or when administered (in conjunction with warfarin) as inpatient treatment of acute DVT with or ...

Most of the newer anticoagulants with FDA-approved labeling for the management of VTE and ACS are primarily eliminated by renal clearance. It is therefore important to consider whether patients ...

A phase IIa trial has demonstrated that a structural analogue of warfarin is safe, tolerable, and efficacious. Investigators believe that this new anticoagulant, named tecarfarin, will be ...

Keywords /Health and medicine/Clinical medicine/Medical treatments/Drug therapy/Medications/ Anticoagulants /Applied sciences and engineering/Risk management/ Risk reduction /Health and medicine ...

Daiichi Sankyo's new anticoagulant Lixiana should be available on the NHS in England and Wales for the treatment and prevention of recurrent blood clots in the legs and lungs, according to NICE.

Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, ...

“However, the acceptance of these drugs is low due to the scarcity of antidotes for newer anticoagulants like direct thrombin ...

A new study published in the Annals of Internal Medicine found that anticoagulation at therapeutic dose decreased 28-day ...

Bayer and Johnson & Johnson’s Xarelto (rivaroxaban) has been shown to prevent recurrence of thromboembolism in children, paving the way for a potential new indication for the anticoagulant.

Antiphospholipid antibodies, including lupus anticoagulant assays run on automated coagulation platforms are one part of the panel of tests recommended to screen and diagnose aPS. As a member of the ...